Profile data is unavailable for this security.
About the company
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
- Revenue in USD (TTM)8.95m
- Net income in USD-21.49m
- Incorporated1990
- Employees75.00
- LocationLineage Cell Therapeutics Inc2173 Salk Ave Ste 200CARLSBAD 92008-7354United StatesUSA
- Phone+1 (510) 521-3390
- Fax+1 (510) 521-3389
- Websitehttps://lineagecell.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P3 Health Partners Inc | 1.27bn | -57.77m | 212.26m | 400.00 | -- | 0.5512 | -- | 0.1676 | -0.6494 | -0.6494 | 13.37 | 1.22 | 1.46 | -- | 13.23 | 3,165,938.00 | -21.46 | -- | -96.06 | -- | 2.50 | 0.1781 | -14.72 | -56.93 | -- | -10.33 | 0.1999 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| Ovid Therapeutics Inc | 391.69k | -52.34m | 212.43m | 40.00 | -- | 2.42 | -- | 542.35 | -0.7415 | -0.7415 | 0.0056 | 1.24 | 0.0026 | -- | -- | 9,792.25 | -34.98 | -20.78 | -37.27 | -23.27 | -- | -- | -13,362.34 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| AVITA Medical Inc | 50.14m | -35.38m | 213.11m | 207.00 | -- | 4.32 | -- | 4.25 | -1.40 | -1.40 | 1.98 | 1.91 | 0.4778 | 1.96 | 8.48 | 242,236.70 | -33.71 | -- | -38.04 | -- | 84.93 | -- | -70.56 | -- | 7.46 | -35.33 | 0.448 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| Coherus Biosciences Inc | 257.24m | -237.89m | 217.98m | 306.00 | -- | -- | -- | 0.8474 | -2.56 | -2.56 | 2.74 | -1.72 | 0.4633 | 3.14 | 1.39 | 840,666.70 | -42.85 | -21.43 | -74.34 | -29.32 | 38.19 | 79.01 | -92.48 | -36.56 | 1.24 | -4.77 | 1.69 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 219.27m | -- | -- | -- | -- | -- | -- | -- | -- | -0.0149 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Werewolf Therapeutics Inc | 16.22m | -41.58m | 219.45m | 46.00 | -- | 1.86 | -- | 13.53 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Merrimack Pharmaceuticals Inc | 0.00 | -1.18m | 219.72m | -- | -- | 11.57 | -- | -- | -0.0826 | -0.0826 | 0.00 | 1.31 | 0.00 | -- | -- | -- | -6.05 | -23.52 | -6.22 | -26.08 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.51 | -- | -- | -- |
| Compass Therapeutics Inc. | 0.00 | -42.49m | 220.14m | 32.00 | -- | 1.38 | -- | -- | -0.3343 | -0.3343 | 0.00 | 1.16 | 0.00 | -- | -- | 0.00 | -23.84 | -41.75 | -25.56 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Agenus Inc | 161.42m | -239.61m | 220.28m | 389.00 | -- | -- | -- | 1.36 | -12.68 | -12.68 | 8.49 | -9.59 | 0.4823 | -- | 170.54 | 414,951.20 | -74.69 | -55.02 | -242.74 | -115.31 | 99.43 | -- | -154.88 | -102.92 | -- | -1.25 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| Lineage Cell Therapeutics Inc | 8.95m | -21.49m | 220.89m | 75.00 | -- | 3.23 | -- | 24.69 | -0.1243 | -0.1243 | 0.0518 | 0.3624 | 0.0796 | -- | 17.17 | 119,266.70 | -19.12 | -19.53 | -22.55 | -22.59 | 92.50 | 89.13 | -240.12 | -370.88 | -- | -- | 0.0023 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -30.01m | 223.99m | 10.00 | -- | 1.97 | -- | -- | -0.5080 | -0.5080 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -19.39 | -36.79 | -22.08 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1182 | -- | -- | -- | 39.47 | -- | -- | -- |
| 2Seventy Bio Inc | 71.20m | -223.22m | 225.15m | 274.00 | -- | 1.09 | -- | 3.16 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Emergent Biosolutions Inc | 1.19bn | -565.30m | 227.95m | 1.60k | -- | 0.3433 | -- | 0.1923 | -10.87 | -10.87 | 22.86 | 12.67 | 0.4988 | 1.99 | 6.09 | 740,875.00 | -23.79 | -2.94 | -38.89 | -3.66 | 41.19 | 53.24 | -47.69 | -5.95 | 0.5538 | 0.0636 | 0.5771 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| AC Immune SA | 16.33m | -59.84m | 229.15m | 133.00 | -- | 1.29 | -- | 14.03 | -0.7082 | -0.7082 | 0.1923 | 1.79 | 0.0803 | -- | 1.92 | 122,791.30 | -29.41 | -18.25 | -31.56 | -19.52 | -- | -- | -366.41 | -148.29 | -- | -89.52 | 0.0213 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| Puma Biotechnology Inc | 226.63m | 15.38m | 232.03m | 185.00 | 14.94 | 4.55 | 8.62 | 1.02 | 0.3219 | 0.3219 | 4.74 | 1.06 | 1.10 | 10.95 | 8.13 | 1,225,016.00 | 7.49 | -12.21 | 11.65 | -20.53 | 73.44 | 78.78 | 6.78 | -11.79 | 1.38 | 2.57 | 0.6624 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
Data as of May 11 2024. Currency figures normalised to Lineage Cell Therapeutics Inc's reporting currency: US Dollar USD
42.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Broadwood Capital, Inc.as of 06 Feb 2024 | 41.67m | 22.10% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 8.08m | 4.28% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 7.87m | 4.17% |
| Greenway Partners LPas of 20 Jul 2023 | 6.85m | 3.63% |
| Defender Capital LLCas of 31 Mar 2024 | 4.97m | 2.64% |
| Geode Capital Management LLCas of 31 Dec 2023 | 2.94m | 1.56% |
| Raffles Capital Management LLCas of 31 Dec 2023 | 2.13m | 1.13% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.10m | 1.11% |
| Prescott General Partners LLCas of 31 Dec 2023 | 1.85m | 0.98% |
| MAI Capital Management LLCas of 31 Mar 2024 | 1.49m | 0.79% |
More ▼
Data from 20 Jul 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
